Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
Subset of anaplastic glioma patients benefit from adjuvant chemo

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.16
Views: 1924

Dr Martin van den Bent - Erasmus MC Cancer Center, Rotterdam, The Netherlands

Dr van den Bent talks to ecancertv at ASCO 2016 about the early results from a European phase III trial which looked at the use of adjuvant temozolomide in anaplastic glioma.

It was found that anaplastic glioma patients without 1p/19q co-deletion benefited from this.

The addition of adjuvant temozolomide also delayed disease progression by more than two years.

Read the news story or watch the press conference video for more.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation